Dyslipidemia during sirolimus therapy in patients after liver transplantation

Clinical Transplantation

Volumn 18, Issue 6, 2004, Pages 642-646

  Kniepeiss, Daniela ^a   Iberer, F ^a   Schaffellner, S ^a   Jakoby, E ^a   Duller, D ^a   Tscheliessnigg, K H ^a  

^a UNIVERSITY HOSPITAL GRAZ   (Austria)

Author keywords

Atherosclerosis; Hyperlipidemia; Liver transplantation; Long term survivor; Sirolimus

Indexed keywords

ANTILIPEMIC AGENT; CALCINEURIN INHIBITOR; CHOLESTEROL; CYCLOSPORIN A; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMMUNOSUPPRESSIVE AGENT; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; LYMPHOCYTE ANTIBODY; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; RAPAMYCIN; TACROLIMUS; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; ATHEROSCLEROSIS; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL PROTOCOL; CONTROLLED STUDY; DIABETES MELLITUS; DIET RESTRICTION; DRUG BLOOD LEVEL; DYSLIPIDEMIA; FEMALE; GRAFT REJECTION; HUMAN; HUMAN TISSUE; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; HYPERTENSION; HYPERTRIGLYCERIDEMIA; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; INFECTION; LEUKOPENIA; LIVER TRANSPLANTATION; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MEDICAL LITERATURE; NEPHROTOXICITY; PATIENT MONITORING; PRIORITY JOURNAL; RASH; RECIPIENT; RETROSPECTIVE STUDY; RISK ASSESSMENT; SURVIVAL TIME; THROMBOCYTOPENIA;

ADULT; AGED; FEMALE; HUMANS; HYPERLIPIDEMIAS; IMMUNOSUPPRESSIVE AGENTS; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; POSTOPERATIVE COMPLICATIONS; RETROSPECTIVE STUDIES; SIROLIMUS;

EID: 8644231871     PISSN: 09020063     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1399-0012.2004.00253.x     Document Type: Article

References (13)

1. Mathe D, Adam R, Malmendier C. Prevalence of dyslipidemia in liver transplant recipients. Transplantation 1992: 54: 167.
2. Trotter JF, Wachs M, Bak T et al. Liver transplantation using sirolimus and minimal corticosteroids (3-day taper). Transplantation 2001: 7 343.
3. Steinmüller TM, Gräf KJ, Schleicher J et al. The effect of FK 506 vs. cyclosporine on glucose and lipid metabolism-a randomized trial. Transplantation 1994: 58: 669.
4. Starzl TE, Fung J, Jordon M, Shapiro R. Kidney transplantation under FK 506. JAMA 1990: 264: 63.
5. Watson CJE, Friend PJ, Jamieson NV et al. Sirolimus: a potent new immunosuppressant for liver transplantation. Transplantation 1999: 67: 505.
6. Groth CG, Backman L, Morales JM, Calne R, Kreis H, Lang P. Sirolimus (rapamycin)-based therapy in human renal transplantation. Transplantation 1999: 67: 1036.
7. Kahan BD for the Rapamune study group. Efficacy of sirolimus compared with azathioprine for reduction of acute renal allograft rejection. Lancet 2000: 356: 194.
8. Svensson JO, Brattström CH, Säwe J. A simple HPLC method for determination of mycophenolic acid and mycophenolic acid glucuronide in plasma. Ther Drug Monitor 1999: 21: 322.
9. Kniepeiss D, Iberer F, Grasser B, Schaffellner S, Tscheliessnigg KH. Sirolimus in patients after liver transplantation. Transpl Proc 2003: 35: 815.
10. Grundy SM. National Cholesterol Education Program. Second report of the Expert Panel on Detection, Evaluation and Treatment of high blood cholesterol in adults (Adult Treatment Panel II). Circulation 1994: 89: 1329.
11. Miller LW. Allograft vascular disease: a disease not limited to hearts. J Heart Lung Transplant 1992: 11: 32.
12. Kobashigawa JA, Kasiske BL. Hyperlipidemia in solid organ transplantation. Transplantation 1997: 63: 331.
13. Valantine HA, Brozena SC, Hobbs R. A randomized double blind placebo-controlled dose-response study to assess the safety and efficacy of oral sirolimus (Rapamycin) in the treatment of acute grade 2 or grade 3a cardiac allograft rejection. Transplantation, in press.